Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Shares of Hims & Hers Health dropped 22% in premarket trading as efforts by drugmakers with weight-loss treatments threaten to erase gains the company has made with its own similar offerings. Shares are trading around $40 in premarket trading.
Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.
Hosted on MSN7d
Morgan Stanley Downgrades Hims & Hers Health (HIMS)Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...
Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...
Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) saw unusually-high trading volume on Friday after Bank of America raised their price target on the stock from $18.00 to $21.00. Bank of ...
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. About This ...
Morgan Stanley also drew scrutiny previously for fielding an all-white, all-male slate of candidates to succeed former CEO ...
Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback